Here, you will find information about submission deadlines and delivery times for letters and packages before Christmas.

Continue reading →

The web pages that concern the printing of doctoral theses are now beginning to be completed.

Here is the UiB page.

Here is Skipnes’s page.

We remind you that PhD candidates should start to book printing services at Skipnes from 1 December. The Research Administration will add the new web pages into the regular UiB / PhD structure later next Thursday or early next Friday.

If you have comments on languages, forms or functionalities, these can be sent to Yngve Brynjulfsen (for the UiB page) or to Idar Klein at Skipnes (with a copy to Yngve).

Best regards, Yngve Brynjulfsen

adviser / PhD coordinator

Research Administration Department, UiB

Dear Researchers from the Department of Clinical Medicine (K1), Department of Clinical Science (K2) and Helse-Bergen.

Have you presented your research at a conference this year?

Then, you are hereby invited to present your work to fellow researchers and the general audience at the Annual Research Presentations arranged by the Research School in Clinical Medicine in January 2018.

If you have presented a poster or had an oral presentation at a scientific meeting or a conference in 2017, you are welcome to present your work at our conference during week 4 of 2018 (dates will be announced soon). You can submit one contribution – either a poster or an oral presentation.

Send abstract (if oral presentations) or abstract and poster (if poster presentation) to forskningspresentasjoner.forskerskolen@uib.no. Abstract should be possible to open with Microsoft Word and posters should be sent as a pdf file. Mark the file(s) and your mail’s subject with your name and the affiliation you have (K1, K2 or Helse-Bergen). Specify whether you want to have an oral or poster presentation. As in previous years, we would like to have a short Norwegian summary which is easy to understand for a general audience, typically five sentences long.

Deadline for submission: 7 December 2017.

Kind regards,

Andreas, Vojtech and Torbjørn

– The Research School in Clinical Medicine –

Continue reading →

Dear all,

The Postgradute School of Clinical Medicine is preparing a new Network Luncheon for all PhD fellows and researchers at K1 and K2 departments.

Now is the time to sign up as a presenter, if you would like to present your latest results, engage in discussion with other PhD students and practice your presentation skills.

The upcoming Network Luncheon will take place Wednesday 6 December, in the Konferanserom of BBB (in front of auditoriums 2 and 4), from 11:30 to 13:00.

Register your participation here

Take a break from your daily lab-routine and enjoy a free lunch, socialize and hear talks from fellow PhD students, and on top of all that, earn one ECTS point!

If you would like to earn one ECTS by signing up for “Seminar in clinical and translational medicine” (FSKLI901), please contact Solveig Lund Witsø.

 Feel free to contact us with any questions you may have!

Looking forward,

Solveig and Yasaman

Since 2002, the Lefoulon-Delalande Institut de France Foundation has awarded an annual Scientific Grand Prize, of an amount of 500,000 euros, to a scientist who has made important contributions to cardiovascular physiology, biology, or medicine. Taken in the widest sense, these fields also include developmental biology, genetics, epidemiology, physiology, as well as clinical biology, imaging techniques, therapeutics, and the pharmacology of the cardiovascular system. The call for nominations for the Scientific Grand Prize 2018 is now open.

More information and nomination form is available here.

Deadline for nominations: 29 January 2018.

Each candidate’s application will be examined by a scientific council composed of experts who are members of the French Academy of Sciences as well as by external experts.

After a bidding process, Skipnes AS now takes over as business card supplier, master’s theses, doctoral theses and doctoral degree at UiB.

The launch of the new printing services will be 1 December, and all new orders must therefore be submitted to Skipnes AS from Friday 1 December. Orders that are in process before this date will be completed by the current supplier, AiT Bjerch.

Links on the faculty web pages will be updated.

The Norwegian Cancer Society awarded 170 million through their Open Call 2017, the University of Bergen received 54,7 million whereas 4 projects from K2 were awarded in total 34,6 million! In addition Stian Knappskog received a supplementary honorary prize as «Project with best user contribution», see more specific below.

Happy UiB Cancer Flag-ship researchers, Rector and Secretary General, flanked by Dean and Hospital Director.

The award ceremony took place at Bikuben Monday 6^th of November, where the Norwegian cancer Society’s secretary general Anne Lise Ryel confirmed that these funding were awarded to the leading Norwegian cancer research environment. University rector Dag Rune Olsen was not less bold: Although Norwegian research traditionally is rather hushed, by continuing our hard, systematic work Norwegian research may well achieve global impact!

Dean of the medical Faculty Per Bakke underlined that these funding (and the resulting research) should benefit the patients! The user perspective was solidly based this year: the Cancer Society had incorporated user representatives in their evaluation process. One of these representatives, Bamse Mork Knudsen, confirmed that user contribution strengthen the legitimacy and trust of research. Although they themselves were somewhat uncertain of their specific role in the process, he urged researcher to not hesitate in incorporating user contributors: «Just do it!»

One which had incorporated this in such exemplary fashion that he was awarded the first « Cancer Society User Contribution Prize», was Stian Knapskog. He was awarded 8,9 million for his project «Uncovering the genetic causes of resistance to chemotherapy in breast cancer» and explains the user focus in this way: «Within the research environment of breast cancer we have, especially the clinicians Per E Lønning and Hans P. Eikesdal, a longstanding good cooperation with the Breast Cancer (patient) Society, both nationally and locally in Bergen. In this year’s application, and with future projects, we have formalized this contact by establishing a user-advisory board. The representatives have been appointed by the Breast Cancer Society, and the board will meet biannually, receive updates regarding the ongoing projects and contribute with advice/inputs for the researchers.» May this be an inspiration for all of us!

Per Lønning was awarded 8,5 millioner for the project «Genome-directed breast cancer therapy». This funding is part of this year’s «Collective effort against cancer» fund rising. The research program consists of two clinical studies whose aim is to find more targeted therapy for patients with primary breast cancer and patients with metastatic breast cancer disease.

An important goal is to design new targeted chemotherapy regimens for patients with tumors associated with poor prognosis. For these patients, a new chemotherapy regimen, possibly a targeted drug, is given.

Camilla Krakstad was awarded 9,2 million with her project «Individualized treatment of endometrial cancer». This was the only Cancer Society funding awarded for gynaecological cancer research this year. Krakstad’s project involves extensive mapping of changes in both primary and metastatic tumors. New identified targets for treatment in the metastatic tumors will be investigated in advanced disease models where the effect of new drugs is tested. The findings from these investigations will provide a better basis for selecting medication for further clinical testing. A clinical study of new markers will investigate whether these can be used in daily routine to choose optimal surgical treatment for patients. The overall goal is to find better and more individually tailored treatment for uterine cancer.

Bjørn Tore Giertsen first described how he had used all former grants he had recived from the Cancer Society. This year he was awarded 8 million from the «Collective effort against cancer» fund rising for his project «Development of novel combined CSF 1R/FLT3-targeted therapy in acute leukemia». Acute myeloid leukemia is an aggressive hematopoietic stem cell disease with less than 20% overall survival after five years. Signal transduction pathways, like receptor tyrosine kinases, are mutated in more than half of the patients. The project will explore the biology of receptor tyrosine kinases CSF1R and FLT3 in acute leukaemia, and develop CSF1R/FLT3 targeted therapy for acute leukaemia along with biomarkers for early detection of therapy non-responders. Mass cytometry will be used to monitor single cell perturbations in intracellular signaling systems combined with immune modulation in blood and bone marrow.

Heartily congratulations from all of us in K2!

Jone Trovik

From left Frode Jahren (Secretary General of LHL), Frode Gallefoss and John Normann Melheim (Chairman of the LHL). Photo: Mari Larsen (Ass. Secretary General in LHL).

Professor at Department of Clinical Science, University of Bergen, and Research Manager at Sørlandet Hospital, Frode Gallefoss, was on 15 November 2017 awarded by the National Association for Heart and Lung Diseases’ (LHL’s) chairman, John Normann Melheim, for outstanding scientific work in chronic obstructive pulmonary disease (COPD). The price is NOK 50,000. Frode Gallefoss is an international researcher who has developed better prevention, patient training and treatment of people with COPD. Epochal was his innovative utility-cost studies of patient education programs. Earlier, he has received the WHO’s Gold Medal for International Anti-Tobacco Work and the Quality Assurance Prize of the Norwegian Medical Association.

K2 congratulates!

(The review is an excerpt from the committee’s recommendation.)